Citigroup
URGN icon

Citigroup’s UroGen Pharma URGN Stock Holding History

Citigroup’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$842K Buy
22,871
+17,928
+363% +$486K ﹤0.01% 3575
2026
Q1 		$88.9K Buy
4,943
+1,541
+45% +$30.9K ﹤0.01% 4329
2025
Q4 		$79.7K Sell
3,402
-1,291
-28% -$28K ﹤0.01% 4415
2025
Q3 		$93.6K Sell
4,693
-380,198
-99% -$6.83M ﹤0.01% 4291
2025
Q2 		$5.27M Buy
384,891
+355,614
+1,215% +$3.41M ﹤0.01% 1850
2025
Q1 		$324K Sell
29,277
-8,733
-23% -$93.1K ﹤0.01% 3909
2024
Q4 		$405K Buy
38,010
+9,882
+35% +$118K ﹤0.01% 3978
2024
Q3 		$357K Buy
28,128
+19,796
+238% +$294K ﹤0.01% 3950
2024
Q2 		$140K Buy
8,332
+3,494
+72% +$49.7K ﹤0.01% 4059
2024
Q1 		$72.6K Sell
4,838
-13,846
-74% -$226K ﹤0.01% 4442
2023
Q4 		$280K Buy
18,684
+18,278
+4,502% +$237K ﹤0.01% 3764
2023
Q3 		$5.69K Sell
406
-5,818
-93% -$93.4K ﹤0.01% 4685
2023
Q2 		$64.4K Sell
6,224
-48,686
-89% -$537K ﹤0.01% 4492
2023
Q1 		$507K Buy
54,910
+295
+0.5% +$2.71K ﹤0.01% 3120
2022
Q4 		$484K Buy
54,615
+54,284
+16,400% +$514K ﹤0.01% 3198
2022
Q3 		$3K Sell
331
-410
-55% -$3.39K ﹤0.01% 5422
2022
Q2 		$6K Sell
741
-486
-40% -$3.34K ﹤0.01% 5570
2022
Q1 		$11K Sell
1,227
-4,385
-78% -$34.2K ﹤0.01% 5489
2021
Q4 		$53K Buy
5,612
+2,169
+63% +$30.6K ﹤0.01% 5037
2021
Q3 		$58K Buy
3,443
+1,138
+49% +$18K ﹤0.01% 4662
2021
Q2 		$35K Buy
2,305
+574
+33% +$10.4K ﹤0.01% 4991
2021
Q1 		$34K Sell
1,731
-2,695
-61% -$57.2K ﹤0.01% 4932
2020
Q4 		$80K Buy
4,426
+2,173
+96% +$45.5K ﹤0.01% 5719
2020
Q3 		$43K Sell
2,253
-4,751
-68% -$108K ﹤0.01% 5701
2020
Q2 		$183K Buy
7,004
+245
+4% +$5.99K ﹤0.01% 5079
2020
Q1 		$121K Buy
6,759
+1,376
+26% +$37.2K ﹤0.01% 5192
2019
Q4 		$180K Buy
5,383
+3,881
+258% +$106K ﹤0.01% 5272
2019
Q3 		$35K Sell
1,502
-4,230
-74% -$138K ﹤0.01% 6366
2019
Q2 		$206K Buy
5,732
+5,424
+1,761% +$200K ﹤0.01% 5246
2019
Q1 		$11K Buy
+308
New +$12.9K ﹤0.01% 7228

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Citigroup's URGN Position: Q2 2026 in Review

Citigroup increased its UroGen Pharma (URGN) stake by 363% in Q2 2026, buying an estimated $486K and bringing the position to 22,871 shares worth $842K. The position accounts for ﹤0.01% of the portfolio, ranked #3575.

Citigroup first reported a position in URGN in Q1 2019 and has held it in 30 quarters since. The position peaked at $5.27M in Q2 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Citigroup held 22,871 shares of UroGen Pharma worth $842K as of Q2 2026.
  • Citigroup bought 17,928 UroGen Pharma shares in Q2 2026, an estimated $486K.
  • UroGen Pharma made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3575 holding.
  • Citigroup first reported a position in UroGen Pharma in Q1 2019 and has held it in 30 quarters since.
  • Citigroup's UroGen Pharma position peaked at $5.27M in Q2 2025.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.